Bozhao Li
Overview
Explore the profile of Bozhao Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu S, Wu Z, Lu Z, Qi F, Cheng J, Chu T, et al.
Cell Rep Med
. 2025 Feb;
:101984.
PMID: 40020674
Despite the transformative impact of programmed cell death protein-1 (PD-1) blockade therapy on metastatic/advanced solid tumor treatment, its efficacy is hindered by a limited response rate. Platelets play a pivotal...
2.
Zeng X, Wang Z, Zhao A, Wu Y, Wang Z, Wu A, et al.
Nat Mater
. 2025 Jan;
24(2):287-296.
PMID: 39815063
A successful therapeutic outcome in the treatment of solid tumours requires efficient intratumoural drug accumulation and retention. Here we demonstrate that zinc gluconate in oral supplements assembles with plasma proteins...
3.
Yang Z, Tian H, Chen X, Li B, Bai G, Cai Q, et al.
Nat Commun
. 2024 Oct;
15(1):9097.
PMID: 39438438
Neoadjuvant immunochemotherapy (nICT) has dramatically changed the treatment landscape of operable esophageal squamous cell carcinoma (ESCC), but factors influencing tumor response to nICT are not well understood. Here, using single-cell...
4.
Wu Z, Li B, Qie Y, Wu S, Qi F, Chu T, et al.
Nano Lett
. 2024 Aug;
24(33):10186-10195.
PMID: 39136297
Despite its significant clinical efficacy as a first-line treatment for advanced bladder cancer, cisplatin-based chemotherapy provides a limited benefit for patients with lymphovascular invasion (LVI), which is characterized by the...
5.
Li S, Lu Z, Wu S, Chu T, Li B, Qi F, et al.
Nat Rev Cancer
. 2023 Dec;
24(1):72-87.
PMID: 38040850
Systemic antiplatelet treatment represents a promising option to improve the therapeutic outcomes and therapeutic efficacy of chemotherapy and immunotherapy due to the critical contribution of platelets to tumour progression. However,...
6.
Wang Z, Sun H, Tang Z, Li B, Qian J, Zhang C
J Contam Hydrol
. 2023 Nov;
259:104265.
PMID: 37980823
Nuclide transport in fractured media involves the advection, dispersion, adsorption, etc. The dispersion and adsorption properties of the rock matrix have spatial variability, which results in an anomalous transport of...
7.
Jiang Z, Cai Z, Hui N, Li B
Sensors (Basel)
. 2023 Nov;
23(21).
PMID: 37960588
Accurately calibrating camera-LiDAR systems is crucial for achieving effective data fusion, particularly in data collection vehicles. Data-driven calibration methods have gained prominence over target-based methods due to their superior adaptability...
8.
Chu T, Cao B, Wang P, Li B, Ren J, Nie G, et al.
Bioconjug Chem
. 2023 Oct;
34(10):1894-1901.
PMID: 37787935
As a pleiotropic cytokine, interleukin-2 (IL-2) can effectively regulate lymphocyte proliferation, survival, and active antitumor immune responses in tumor microenvironments. Although the ability of IL-2 to boost immune responses was...
9.
Li B, Lu Z, Yang Z, Zhang X, Wang M, Chu T, et al.
Cell Rep Methods
. 2023 Aug;
3(7):100513.
PMID: 37533637
A characteristic clinical complication in cancer patients is the frequent incidence of thrombotic events. Numerous studies have shown hyperactive/activated platelets to be a critical earlier trigger for cancer-associated thrombus formation....
10.
Li B, Qi F, Zhu F, Lu Z, Wang M, Chu T, et al.
Cancer Res
. 2023 Jun;
83(17):2924-2937.
PMID: 37326467
Significance: A smart nanomedicine encapsulating fulvestrant to improve its half-life, bioavailability, and tumor-targeting and coloaded with CDK4/6 inhibitor abemaciclib to block resistance is a safe and effective therapy for ER-positive...